Clinical trial
G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety
NCT02656069 is registered in ClinicalTrials.gov with Xeris Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety
- Lead sponsor
- Xeris Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 15, 2017
- Completion date
- September 25, 2017
- Enrollment
- 80 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.